SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vivimed Labs (Alathur) Pvt Ltd. - (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Vivimed Labs(Alathur Share Price

BSE Share Price
Not Listed

Vivimed Labs (Alathur) Pvt Ltd. - (Amalgamated)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Vivimed Labs(Alathur Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹0
TTM Sales
₹36.2 Cr.
Book Value per Share
-
P/E Ratio
0.00
Industry PE
50
Price to Book (P/B)
0.00
Price to Sales (P/S)
0.00
EV/EBITDA
0.00
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
-10.78%
Return on Capital Employed (ROCE)
-5.60%
Return on Assets (ROA)
-7.70%
Operating Profit Margin
-7.1%
Net Profit Margin
-27.13%
Gross Profit Margin
-13.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
28.55%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
₹36 Cr.
Equity
₹0 Cr.
Face Value
₹10
All Time Low / High
- / -

Vivimed Labs (Alathur) Pvt . - (Amalgamated) stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16TTM
ROCE % -9.6%0.4%4.9%2.4%18.1%3.2%-6.4%-5.9%-5.6%-

Growth Parameters

Sales 5.933.526.484.715217975.628.136.236
Sales YoY Gr.-467.3%-21.3%221%79.3%18.2%-57.9%-62.8%28.6%-
Adj EPS -349.2-0.10.60.32.1-0.5-2.5-1.1-1.90
YoY Gr.-NANA-50.9%635.7%-121.8%NANANA-
BVPS (₹) -339.218.719.320.42322.616.219.117.20
Adj Net
Profit
-7-0.33.41.813.6-3-12.5-5.5-9.70
Cash Flow from Ops. 000030.6-17.37423.29.5-
Debt/CF from Ops. 00000.5-2.30.20.71.8-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NA-15.7%-41.4%28.6%
Adj EPS NA-247.3%NANA
BVPSNA-3.4%-8.8%-10.2%
Share Price - - - -

Key Financial Parameters

Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16TTM
Return on
Equity %
-7.4-0.331.59.6-2-12.4-5.6-10.70
Op. Profit
Mgn %
-94.619.449.914.924.38.4-7.8-11.5-7.1NAN
Net Profit
Mgn %
-118.2-112.82.19-1.7-16.5-19.6-26.90
Debt to
Equity
-0.800.10.20.10.30.20.20.2-
Working Cap
Days
01923562252082263888986010
Cash Conv.
Cycle
0-129141791521941281110

Profit And Loss

(All Figures are in Crores.)
PARTICULARSDec'07Dec'08Dec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16
Sales5.9133.5326.3884.69151.81179.4794.4828.1336.16
Operating Expenses + 11.5027.0413.2172.09114.99164.71101.8531.4138.86
Manufacturing Costs2.396.875.435.1511.9015.2610.064.416.05
Material Costs2.562.795.2148.3976.78112.4668.6915.3420.76
Employee Cost 000018.2419.3416.527.847.55
Other Costs 6.5517.382.5718.558.0717.646.583.824.49
Operating Profit -5.596.4913.1812.6036.8214.76-7.37-3.28-2.70
Operating Profit Margin (%) -94.6%19.4%49.9%14.9%24.3%8.2%-7.8%-11.7%-7.5%
Other Income + 00001.142.657.970.110.16
Exceptional Items 00003.550.40000
Interest 00003.013.931.691.712.65
Depreciation 3.996.077.379.2011.9912.1910.393.663.49
Profit Before Tax -9.590.425.803.4026.501.70-11.48-8.54-8.67
Tax -2.600.742.431.619.804.58-1.39-3.011.14
Profit After Tax -6.98-0.323.371.7916.70-2.88-10.09-5.53-9.81
PAT Margin (%) -118.0%-1.0%12.8%2.1%11.0%-1.6%-10.7%-19.7%-27.1%
Adjusted EPS (₹)-349.0-0.10.60.32.5-0.4-2.0-1.1-2.0
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%

Valuation of Vivimed Labs(Alathur - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSDec'07Dec'08Dec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16

Equity and Liabilities

Shareholders Fund + -6.78109.44113.88132.07151.69148.81101.6595.8986.08
Share Capital 0.2058.4859.0164.9065.8865.8850.1750.1750.17
Reserves -6.9850.9754.8767.1785.8282.9351.4845.7235.91
Debt +5.243.598.4427.9610.3340.0517.5216.7016.72
Long Term Debt5.243.598.4427.9610.3340.0517.524.753.87
Short Term Debt000000011.9512.85
Minority Interest000000000
Trade Payables4.586.188.5428.3524.8014.553.584.6010.22
Others Liabilities 99.50-1.261.593.4430.2111.9711.209.5315.08
Total Liabilities 102.53117.95132.45191.81217.03215.38133.96126.72128.10

Fixed Assets

Net Fixed Assets +77.6886.8887.19100.79110.1787.2851.8949.6747.17
Gross Block82.4597.86105.36123.03142.99141.0685.1986.6287.62
Accumulated Depreciation4.7710.9818.1722.2432.8353.7833.3036.9540.44
CWIP 7.736.8415.9815.315.6900.5310.7316.18
Investments 0.1100000000
Inventories5.278.0210.2027.2342.7718.138.973.355.47
Trade Receivables1.066.3110.1321.3041.5491.960.1915.9812.83
Cash Equivalents 4.411.650.450.093.803.211.101.604.97
Others Assets 6.288.258.4927.0913.0614.7971.2745.3941.47
Total Assets 102.53117.95132.45191.81217.03215.38133.96126.72128.10

Cash Flow

(All Figures are in Crores.)
PARTICULARSDec'11Dec'12Mar'14Mar'15Mar'16
Cash Flow From Operating Activity + 30.61-17.2892.4723.239.51
PBT 26.501.70-11.48-8.54-8.67
Adjustment 16.0334.865.295.626.46
Changes in Working Capital -9.89-48.2998.6726.1511.73
Tax Paid -2.03-5.55000
Cash Flow From Investing Activity + -13.82-6.5324.48-11.78-6.30
Capex -13.87-6.5524.48-11.84-6.45
Net Investments 00000
Others 0.040.02-00.060.14
Cash Flow From Financing Activity + -13.0823.21-119.06-10.950.16
Net Proceeds from Shares 2.920-37.0600
Net Proceeds from Borrowing 00000
Interest Paid -2.67-2.24-1.39-1.71-2.65
Dividend Paid 00000
Others -13.3325.46-80.61-9.242.81
Net Cash Flow 3.71-0.59-2.110.503.37

Financial Ratio

PARTICULARSDec'07Dec'08Dec'09Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16
Ratios
ROE (%)N/A-0.633.021.4611.77-1.92-8.06-5.6-10.78
ROCE (%)N/A0.394.932.4118.093.17-6.36-5.9-5.6
Asset Turnover Ratio0.060.30.210.520.740.830.550.230.3
PAT to CFO Conversion(x)N/AN/A27.4412.980.57N/AN/AN/AN/A
Working Capital Days
Receivable Days65.2040.10113.7067.7075.60135.80174100.10139.20
Inventory Days325.4072.3012680.7084.2061.9051.2076.3042.60
Payable Days653.30703.90515.20139.10126.3063.9048.2097.30130.20

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vivimed Labs (Alathur) Pvt Ltd. - (Amalgamated) FAQs

The current trading price of Vivimed Labs(Alathur on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Vivimed Labs(Alathur stood at ₹0.00 Cr

The latest P/E ratio of Vivimed Labs(Alathur as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Vivimed Labs(Alathur as of 31-Dec-1969 is 0.00.

The 52-week high of Vivimed Labs(Alathur is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vivimed Labs(Alathur is ₹36.16 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Vivimed Labs (Alathur) Pvt Ltd. - (Amalgamated)

No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: